Beta-catenin-activated hepatocellular adenoma in a male.
Fine needle aspiration biopsy
Glutamine synthetase
Hepatocellular adenoma
Malignant transformation
β-Catenin-activated hepatocellular adenoma
Journal
Clinical journal of gastroenterology
ISSN: 1865-7265
Titre abrégé: Clin J Gastroenterol
Pays: Japan
ID NLM: 101477246
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
10
09
2020
accepted:
22
02
2021
pubmed:
3
3
2021
medline:
29
6
2021
entrez:
2
3
2021
Statut:
ppublish
Résumé
Beta-catenin-activated hepatocellular adenoma is potentially malignant and warrants careful follow-up and surgical resection. Here, we report a 48-year-old man in whom a 55 mm single liver tumor was incidentally detected in the S1 segment. Contrast-enhanced computed tomography scans showed no enhancement in the early phase and a slight defection in the late phase. The tumor was enhanced hyperintensity in the hepatobiliary phase on Gd-ethoxybenzyl-diethylenetriaminepentaacetic acid-enhanced magnetic resonance imaging. The histologic features of ultrasound-guided fine-needle aspiration biopsy indicated hepatocellular adenoma, and the tumor was immunohistochemically positive for glutamine synthetase and β-catenin. Considering the risk of malignant transformation, he underwent laparoscopic-assisted partial liver resection. The resected tumor did not contain any malignant lesions. This case indicates that aspiration needle biopsy and immunohistochemistry were useful for histological diagnosis and treatment decisions based on the molecular definition of hepatocellular adenoma.
Identifiants
pubmed: 33651269
doi: 10.1007/s12328-021-01372-z
pii: 10.1007/s12328-021-01372-z
doi:
Substances chimiques
beta Catenin
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
831-835Références
Agrawal S, Agarwal S, Arnason T, et al. Management of hepatocellular adenoma: recent advances. Clin Gastroenterol Hepatol. 2015;13:1221–30.
doi: 10.1016/j.cgh.2014.05.023
Bioulac-Sage P, Laumonier H, Couchy G, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology. 2009;50:481–9.
doi: 10.1002/hep.22995
Nault JC, Couchy G, Balabaud C, et al. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology. 2017;152:880–94.
doi: 10.1053/j.gastro.2016.11.042
Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006;43:515–24.
doi: 10.1002/hep.21068
Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumors of the digestive system; World Health Organization of Tumors. 4th ed. Lyon: IARC; 2010. p. 198–204.
Cho SW, Marsh JW, Steel J, et al. Surgical management of hepatocellular adenoma: take it or leave it? Ann Surg Oncol. 2008;15:2795–803.
doi: 10.1245/s10434-008-0090-0
Farges O, Ferreira N, Dokmak S, et al. Changing trends in malignant transformation of hepatocellular adenoma. Gut. 2011;60:85–9.
doi: 10.1136/gut.2010.222109
Kim DH, Kim SU, Nam DH, et al. A case of hepatocellular carcinoma within hepatocellular adenoma in a non-cirrhotic male. Korean J Intern Med. 2009;24:147–52.
doi: 10.3904/kjim.2009.24.2.147
An SL, Wang LM, Rong WQ, et al. Hepatocellular adenoma with malignant transformation in male patients with non-cirrhotic livers. Chin J Cancer. 2015;34:217–24.
doi: 10.1186/s40880-015-0014-x
van Aalten SM, Verheij J, Terkivatan T, et al. Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. J Hepatol. 2011;55:120–5.
doi: 10.1016/j.jhep.2010.10.030
Védie AL, Sutter O, Ziol M, et al. Molecular classification of hepatocellular adenomas: impact on clinical practice. Hepat Oncol. 2018;5:HEP04.
doi: 10.2217/hep-2017-0023
Yoneda N, Matsui O, Kitao A, et al. Beta-catenin-activated hepatocellular adenoma showing hyperintensity on hepatobiliary-phase gadoxetic-enhanced magnetic resonance imaging and overexpression of OATP8. Jpn J Radiol. 2012;30:777–82.
doi: 10.1007/s11604-012-0115-2
van Aalten SM, Thomeer MG, Terkivatan T, et al. Hepatocellular adenomas: correlation of MR imaging findings with pathologic subtype classification. Radiology. 2011;261:172–81.
doi: 10.1148/radiol.11110023
Fukusato T, Soejima Y, Kondo F, et al. Preserved or enhanced OATP1B3 expression in hepatocellular adenoma subtypes with nuclear accumulation of β-catenin. Hepatol Res. 2015;45:E32–42.
doi: 10.1111/hepr.12453
Bioulac-Sage P, Cubel G, Taouji S, et al. Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes. Am J Surg Pathol. 2012;36:1691–9.
doi: 10.1097/PAS.0b013e3182653ece
Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149:1192–205.
doi: 10.1016/j.cell.2012.05.012